EFR3A and pancreatic adenocarcinoma: Although a limited number of samples, differentiating KRAS mutation-positive (n = 64) from KRAS mutation-negative (n = 115) pancreatic adenocarcinoma samples revealed higher EFR3A expression in the former (Supplementary Fig. 2c).